{"text": ["Supernus", "Pharmaceuticals", "seeks", "FDA", "approval", "for", "ADHD", "drug"], "created_at": "2019-11-12 23:14:41"}
{"text": ["Boehringer", "Ingelheim", "and", "Lilly", "initiate", "first", "ever", "study", "to", "assess", "Jardiance\u00ae", "in", "people", "hospitalized", "for", "acute", "heart", "failure", "who", "have", "been", "stabilized"], "created_at": "2019-11-12 13:30:00"}
{"text": ["ACR", "2019:", "Lilly", "Presents", "52-Week", "Head-to-Head", "(SPIRIT-H2H)", "Data", "from", "Taltz\u00ae", "(ixekizumab)", "Versus", "Humira\u00ae", "(adalimumab)", "Trial", "in", "Psoriatic", "Arthritis"], "created_at": "2019-11-12 12:00:00"}
{"text": ["ACR", "2019:", "Lilly", "Presents", "Positive", "New", "Data", "from", "COAST-X,", "a", "Phase", "3", "Study", "of", "Taltz\u00ae", "(ixekizumab)", "in", "Patients", "with", "Non-Radiographic", "Axial", "Spondyloarthritis"], "created_at": "2019-11-12 11:45:00"}
